1. Home
  2. LAC vs PHAT Comparison

LAC vs PHAT Comparison

Compare LAC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lithium Americas Corp.

LAC

Lithium Americas Corp.

HOLD

Current Price

$3.01

Market Cap

1.0B

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$8.93

Market Cap

969.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAC
PHAT
Founded
2023
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
969.8M
IPO Year
2023
2019

Fundamental Metrics

Financial Performance
Metric
LAC
PHAT
Price
$3.01
$8.93
Analyst Decision
Hold
Strong Buy
Analyst Count
7
6
Target Price
$6.14
$19.83
AVG Volume (30 Days)
9.2M
1.5M
Earning Date
05-14-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
42.72
EPS
N/A
N/A
Revenue
N/A
$175,110,000.00
Revenue This Year
N/A
$93.04
Revenue Next Year
N/A
$58.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
216.93
52 Week Low
$2.53
$8.03
52 Week High
$10.52
$18.31

Technical Indicators

Market Signals
Indicator
LAC
PHAT
Relative Strength Index (RSI) 37.56 34.58
Support Level N/A $8.78
Resistance Level $4.04 $13.17
Average True Range (ATR) 0.14 0.67
MACD 0.05 -0.30
Stochastic Oscillator 53.57 15.83

Price Performance

Historical Comparison
LAC
PHAT

About LAC Lithium Americas Corp.

Lithium Americas Corp is a Canadian-based resource and materials company focused on developing, building and operating lithium deposits and chemical processing facilities. The company also holds investments in Green Technology Metals Limited (GT1) and Ascend Elements, Inc. (Ascend Elements), and exploration properties in the U.S. and Canada. The company's flagship asset is Thacker Pass, a sedimentary-based lithium deposit located in the McDermitt Caldera in Humboldt County, in northern Nevada (Thacker Pass or the Project). The company operates in only one operating segment and one geographical segment.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: